

Kigali, 04/05/2021 Ref N°:DIS/1175/FDA/2021

Phn MUSAFIRI Cyprien **HIV Division** RBC/KIGALI

Dear Sir,

Re: Nomination as member of the National Pharmacovigilance Advisory Committee

Reference is made to the Law N° 003/2018 of 09/02/2018 establishing Rwanda FDA, especially in its article 8 (9), the Authority is mandated to conduct pharmacovigilance and post marketing surveillance for safety and quality of regulated products;

Further reference is also made to the Wold Health organization (WHO) minimum requirements for a functional Pharmacovigilance system where each country is required to have a National Pharmacovigilance Advisory Committee, which will technically advise National Medicine Regulatory Agency (NMRA) on different regulatory measures to be taken for continuous monitoring of the quality and safety of medical products;

I am pleased to inform you that you are nominated as a member of the National Pharmacovigilance Advisory Committee for a period of three (3) years.

Kindly find attached herewith the Terms of Reference of the committee for your information.

I take this opportunity to wish you success in your responsibilities.

Dr. Charles KARANGWA Ag. Director General

- E: Property of Health Ood and Drugs Authority
- **Director General RBC**